Table 1 Descriptive statistics for baseline and follow-up data among patients with psoriasis and/or psoriatic arthritis
Baseline patients’ characteristics | Psoriasis (PsO) N = 25 (30.9%) | Psoriatic arthritis (PsA) N = 7 (8.6%) | PsO-PsA N = 49 (60.5%) | Total N = 81 (100%) | |
|---|---|---|---|---|---|
Demographics | |||||
Age (years) | Mean (SD) | 36.7 (12.9) | 41.3 (10.5) | 42.7 (13.9) | 40.7 (13.5) |
Age of diagnosis (years) | Mean (SD) | 25.3 (12.4) | 30.9 (12.3) | 31.8 (14.0) | 29.7 (13.5) |
Age at starting Secukinumab (years) | Mean (SD) | 34.4 (13.2) | 39.9 (10.4) | 41.3 (13.7) | 39.0 (13.6) |
Disease duration (years) | Median (IQR) | 11.0 (7.0 to 16.0) | 4.0 (3.0 to 10.5) | 10.0 (6.0 to 13.0) | 10.0 (6.0 to 14.0) |
Gender | Male | 13 (52.0) | 3 (42.9) | 20 (40.8) | 36 (44.4) |
Source clinics | Dermatology | 25 (100.0) | 1 (14.3) | 31 (63.3) | 57 (70.4) |
Rheumatology | 0 (0.0) | 6 (85.7) | 18 (36.7) | 24 (29.6) | |
Clinical & comorbidities | |||||
Diabetes Mellitus | Â | 3 (12.0) | 1 (14.3) | 13 (26.5) | 17 (21.0) |
Hypertension | Â | 2 (8.0) | 1 (14.3) | 11 (22.4) | 14 (17.3) |
Ischemic Heart Disease (IHD) | Â | 1 (4.0) | 0 (0.0) | 5 (10.2) | 6 (7.4) |
Lung diseases | Â | 0 (0.0) | 0 (0.0) | 1 (2.0) | 1 (1.2) |
Renal disease | Â | 0 (0.0) | 0 (0.0) | 3 (6.1) | 3 (3.7) |
Depression | Â | 7 (28.0) | 1 (16.7) | 8 (16.3) | 16 (20.0) |
Uveitis | Â | 1 (4.0) | 1 (14.3) | 0 (0.0) | 2 (2.5) |
Neurological disease | Â | 0 (0.0) | 0 (0.0) | 2 (4.1) | 2 (2.5) |
Treatment variables | |||||
Previous exposure to biologics | Â | 13 (52.0) | 3 (42.9) | 38 (77.6) | 54 (66.7) |
Rituximab (RTX) | No | 24 (96.0) | 7 (100.0) | 48 (98.0) | 79 (97.5) |
Stopped | 1 (4.0) | 0 (0.0) | 0 (0.0) | 1 (1.2) | |
Yes | 0 (0.0) | 0 (0.0) | 1 (2.0) | 1 (1.2) | |
Infliximab | Currently | 0 (0.0) | 0 (0.0) | 1 (2.0) | 1 (1.2) |
No | 25 (100.0) | 7 (100.0) | 45 (91.8) | 77 (95.1) | |
Stopped | 0 (0.0) | 0 (0.0) | 3 (6.1) | 3 (3.7) | |
Etanercept | No | 22 (88.0) | 5 (71.4) | 29 (59.2) | 56 (69.1) |
Stopped | 3 (12.0) | 2 (28.6) | 20 (40.8) | 25 (30.9) | |
Adalimumab | No | 14 (56.0) | 5 (71.4) | 29 (59.2) | 48 (59.3) |
Stopped | 11 (44.0) | 2 (28.6) | 19 (38.8) | 32 (39.5) | |
Yes | 0 (0.0) | 0 (0.0) | 1 (2.0) | 1 (1.2) | |
Certolizumab Pegol | Currently | 0 (0.0) | 0 (0.0) | 1 (2.0) | 1 (1.2) |
No | 25 (100.0) | 6 (85.7) | 46 (93.9) | 77 (95.1) | |
Stopped | 0 (0.0) | 1 (14.3) | 2 (4.1) | 3 (3.7) | |
Tofacitinib | Currently | 0 (0.0) | 0 (0.0) | 2 (4.1) | 2 (2.5) |
No | 25 (100.0) | 7 (100.0) | 45 (91.8) | 77 (95.1) | |
Stopped | 0 (0.0) | 0 (0.0) | 2 (4.1) | 2 (2.5) | |
Upadacitinib | Currently | 0 (0.0) | 0 (0.0) | 1 (2.0) | 1 (1.2) |
No | 25 (100.0) | 7 (100.0) | 48 (98.0) | 80 (98.8) | |
Guselkumab | Currently | 4 (16.0) | 2 (28.6) | 6 (12.2) | 12 (14.8) |
No | 20 (80.0) | 5 (71.4) | 41 (83.7) | 66 (81.5) | |
Stopped | 1 (4.0) | 0 (0.0) | 2 (4.1) | 3 (3.7) | |
Secukinumab | Currently | 19 (76.0) | 6 (85.7) | 37 (75.5) | 62 (76.5) |
Stopped | 6 (24.0) | 1 (14.3) | 12 (24.5) | 19 (23.5) | |
Ustekinumab | Currently | 1 (4.0) | 0 (0.0) | 0 (0.0) | 1 (1.2) |
No | 20 (80.0) | 7 (100.0) | 42 (85.7) | 69 (85.2) | |
Stopped | 4 (16.0) | 0 (0.0) | 7 (14.3) | 11 (13.6) | |
Methotrexate | No | 15 (62.5) | 2 (28.6) | 22 (44.9) | 39 (48.8) |
Stopped | 7 (29.2) | 3 (42.9) | 18 (36.7) | 28 (35.0) | |
Yes | 2 (8.3) | 2 (28.6) | 9 (18.4) | 13 (16.2) | |
Disease severity measures (Baseline) | |||||
Disease activity at enrollment | Active | 13 (52.0) | 2 (28.6) | 27 (55.1) | 42 (51.9) |
Mild | 12 (48.0) | 5 (71.4) | 22 (44.9) | 39 (48.1) | |
Peripheral involvement | Â | 0 (0.0) | 7 (100.0) | 48 (98.0) | 55 (96.5) |
Axial involvement | Â | 0 (0.0) | 2 (28.6) | 15 (32.6) | 17 (31.5) |
Swollen Joint Count (SJC) | Median (IQR) | 0.0 (0.0 to 0.0) | 6.0 (5.0 to 6.5) | 6.0 (4.0 to 7.0) | 4.0 (0.0 to 7.0) |
Total Joint Count (TJC) | Median (IQR) | 0.0 (0.0 to 0.0) | 9.0 (7.0 to 10.5) | 7.0 (5.0 to 9.0) | 5.0 (0.0 to 8.0) |
Disease Activity in Psoriatic Arthritis score (DAPSA) | Median (IQR) | 0.0 (0.0 to 0.0) | 29.2 (26.8 to 32.8) | 28.1 (25.0 to 33.2) | 25.1 (0.0 to 30.2) |
Psoriasis Area Severity Index (PASI) | Median (IQR) | 18.0 (12.0 to 20.0) | 0.0 (0.0 to 0.0) | 9.0 (7.0 to 14.0) | 11.0 (8.0 to 18.0) |
Body Surface Area (%) | Median (IQR) | 30.0 (20.0 to 44.0) | 0.0 (0.0 to 0.0) | 15.0 (8.0 to 30.0) | 20.0 (8.0 to 35.0) |
Dermatology Quality of Life Index (DLQI) | Mean (SD) | 15.4 (4.3) | 1.0 (2.4) | 10.8 (5.3) | 11.5 (6.1) |
Human Leukocyte Antigen-B27 | Positive | 0 (0.0) | 0 (0.0) | 1 (2.0) | 1 (1.2) |
Negative | 2 (8.0) | 2 (28.6) | 6 (12.2) | 10 (12.3) | |
Erythrocyte Sedimentation Rate (ESR) | Median (IQR) | 23.0 (16.2 to 52.2) | 29.0 (13.0 to 43.0) | 36.0 (23.0 to 55.8) | 35.5 (22.8 to 53.2) |
C-reactive protein (CRP) | Median (IQR) | 3.7 (2.3 to 6.6) | 1.9 (0.4 to 2.4) | 4.1 (1.8 to 7.3) | 3.7 (1.8 to 6.7) |
Treatment discontinuation | |||||
Inflammatory bowel disease secondary to Secukinumab | Â | 0 (0.0) | 0 (0.0) | 2 (4.1) | 2 (2.5) |
Secukinumab duration (months) | Median (IQR) | 21.0 (10.0 to 35.0) | 24.0 (10.0 to 25.5) | 16.0 (8.0 to 27.0) | 18.0 (9.0 to 28.0) |
Reason of discontinuation | Non-stop | 19 (82.6) | 6 (85.7) | 37 (77.1) | 62 (76.5) |
Active disease | 1 (4.3) | 0 (0.0) | 8 (16.7) | 9 (47.4)a | |
No improvement | 2 (8.7) | 1 (14.3) | 1 (2.1) | 4 (21.1)a | |
Patient controlled | 1 (4.3) | 0 (0.0) | 2 (4.2) | 3 (15.8)a | |
3 months follow-up (%) | Median (IQR) | 50.0 (40.0 to 60.0) | 50.0 (25.0 to 70.0) | 60.0 (40.0 to 80.0) | 60.0 (40.0 to 70.0) |
6 months follow-up (%) | Median (IQR) | 70.0 (60.0 to 80.0) | 70.0 (60.0 to 87.5) | 80.0 (70.0 to 90.0) | 80.0 (60.0 to 90.0) |
12 months follow-up (%) | Median (IQR) | 80.0 (60.0 to 90.0) | 75.0 (67.5 to 82.5) | 90.0 (80.0 to 100.0) | 85.0 (60.0 to 92.5) |
18 months follow-up (%) | Median (IQR) | 90.0 (75.0 to 100.0) | 90.0 (87.5 to 92.5) | 90.0 (80.0 to 100.0) | 90.0 (80.0 to 100.0) |